283 patents
Page 2 of 15
Utility
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
23 Nov 23
Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Paul KRENITSKY, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Jinglan ZHOU
Filed: 6 Oct 21
Utility
Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases
16 Nov 23
Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
Marinus Jacobus VERWIJS, Radhika KARKARE, Michael Douglas MOORE
Filed: 30 Dec 22
Utility
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
16 Nov 23
Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Mark Thomas MILLER, Fabrice PIERRE, Alina SILINA, Jinglan ZHOU
Filed: 6 Oct 21
Utility
DNA-PK inhibitors
14 Nov 23
The present invention relates to compounds useful as inhibitors of DNA-PK.
John Patrick Maxwell, Paul S. Charifson, Qing Tang, Steven M. Ronkin, Katrina Lee Jackson, Albert Charles Pierce, David J. Lauffer, Pan Li, Simon Giroux, Jinwang Xu, Kevin Michael Cottrell, Mark A. Morris, Nathan D. Waal, John J. Court, Wenxin Gu, Hongbo Deng
Filed: 17 Sep 20
Utility
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator
9 Nov 23
Alexander Russell Abela, Timothy Alcacio, Corey Anderson, Paul Timothy Angell, Minson Baek, Jeremy J. Clemens, Thomas Cleveland, Lori Ann Ferris, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Robert M. Hughes, Pramod Virupax Joshi, Ping Kang, Ali Keshavarz-Shokri, Haripada Khatuya, Paul John Krenitsky, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Jean Denis Pierre, Yi Shi, Muna Shrestha, David Andrew Siesel, Kathy Stavropoulos, Andreas P. Termin, Fredrick F. Van Goor, Johnny Uy, Timothy John Young, Jinglan Zhou
Filed: 4 Aug 22
Utility
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
7 Nov 23
Provided are MTSP-1 polypeptides modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation.
Edwin L. Madison, Vanessa Soros, Mikhail Popkov
Filed: 9 Jul 21
Utility
Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
31 Oct 23
Navita Mallalieu, Ifeatu Egbuna, Brian J. Hare, Alexander Wolfgang Krug, Shu-Pei Wu
Filed: 5 Mar 21
Utility
Materials and methods for treatment of pain related disorders
31 Oct 23
The present application provides materials and methods for treating a patient with one or more conditions associated with SCN10A whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 6 Jul 17
Utility
Modulators of ALPHA-1 Antitrypsin
26 Oct 23
Novel compounds, compositions, and methods of using and preparing the same, which maybe useful for treating alpha-1 antitrypsin deficiency (AATD).
Simon GIROUX, Michael Philip CLARK, Qing TANG, Philippe Marcel NUHANT, Peter JONES, David MESSERSMITH, Upul Keerthi BANDARAGE, Kevin Michael COTTRELL, Michael Aaron BRODNEY, Gabrielle Simone FLEMING, Jian WANG, Jinwang XU, Kevin Brett DANIEL, Michael John BOYD, Mark A. MORRIS, Nathan D. WAAL, Philip Noel COLLIER, Sarathy KESAVAN, Steven M. RONKIN, Hongbo DENG, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ
Filed: 2 Apr 21
Utility
Solid Forms of (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE
19 Oct 23
The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
Filed: 22 Nov 22
Utility
Cell Therapy for Diabetes
19 Oct 23
Disclosed herein are compositions, kits, and methods related to cell therapy for a disease characterized by high blood glucose levels over a long period of time, such as diabetes.
Felicia PAGLIUCA, George HARB, Jason GAGLIA, Andrea VERGANI, Christopher THANOS
Filed: 31 Jan 23
Utility
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
5 Oct 23
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
Alexander Russell ABELA, Jeremy J. CLEMENS, Peter Diederik Jan GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Jason McCARTNEY, Mark Thomas MILLER, Fabrice Jean Denis PIERRE, Joe Anh TRAN, Jinglan ZHOU
Filed: 11 Jul 22
Utility
Prodrugs of pyridone amides useful as modulators of sodium channels
3 Oct 23
Corey Anderson, Sara Sabina Hadida Ruah, Julian Marian Charles Golec, Beili Zhang, Benjamin Joseph Littler, Ali Keshavarz-Shokri, Tim Edward Alcacio, Daniel T. Belmont
Filed: 20 Aug 20
Utility
Crystalline Forms of CFTR Modulators
28 Sep 23
Satish Kumar IYEMPERUMAL, Andrey PERESYPKIN, Yi SHI, Muna SHRESTHA
Filed: 12 Aug 21
Utility
Carboxamides As Modulators of Sodium Channels
14 Sep 23
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided.
Nadia M. AHMAD, Corey ANDERSON, Vijayalaksmi ARUMUGAM, Iuliana Luci ASGIAN, Joanne Louise CAMP, Lev Tyler Dewey FANNING, Sara Sabina HADIDA RUAH, Dennis HURLEY, Yvonne SCHMIDT, David SHAW, Urvi PATEL, Stephen Andrew THOMSON, Lidio Marx CARVALHO MEIRELES
Filed: 13 Dec 22
Utility
Substituted Tetrahydrofurans As Modulators of Sodium Channels
14 Sep 23
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided.
Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
Filed: 8 Nov 22
Utility
Pharmaceutical composition and administrations thereof
12 Sep 23
The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
Filed: 15 Sep 21
Utility
Substituted Quinoxaline Dna-pk Inhibitors
7 Sep 23
The present invention relates to compounds useful as inhibitors of DNA-PK.
John Patrick Maxwell, Paul S. Charifson, Qing Tang, Steven M. Ronkin, Katrina Lee Jackson, Albert Charles Pierce, David J. Lauffer, Pan Li, Simon Giroux, Jinwang Xu, Kevin Michael Cottrell, Mark A. Morris, Nathan D. Waal, John J. Court, Wenxin Gu, Hongbo Deng
Filed: 27 Feb 23
Utility
Processes for Preparing Modulators of ALPHA-1 Antitrypsin
7 Sep 23
This disclosure provides large-scale processes for preparing a modulator of alpha-1 antitrypsin (AAT) activity that may be useful for treating alpha-1 antitrypsin deficiency (AATD), such as 4-(5-(4-fluorophenyl)-6-(tetrahydro-2H-pyran -4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid (Compound 1), 3-[5-(4-fluorophenyl)-6-isopropyl-1H-pyrrolo[2,3-f]inda-zol-7-yl]propanoic acid (Compound 2), or a pharmaceutically acceptable salt of any of the foregoing.
Cavan McKeon BLIGH, Robert Daniel GIACOMETTI, Cristian HARRISON, Stephen W. LAWS, Adam LOOKER, Stefanie ROEPER
Filed: 26 Jul 21
Utility
Materials and Methods for Treatment of Pain Related Disorders
7 Sep 23
The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 3 Oct 22